Piperacillin-Tazobactam and Pseudomonas aeruginosa

FDA has reevaluated the rationale document entitled, “Piperacillin-Tazobactam Breakpoints for Pseudomonas aeruginosa” (MR15, January 2024), submitted by the Clinical and Laboratory Standards Institute (CLSI) to susceptibility test interpretive criteria docket...